Use of Section viii statements in pharmaceutical labeling. Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and legislation to reform pharmacy benefit managers. Patent reform legislation. Proposals related to drug shortages. Reauthorization of the Pandemic and All Hazards Preparedness Act (PAHPA). Proposals related to biosimilar drugs. Proposals related to changes in prescription drug labeling. Proposals related to supply chain security and manufacturing.
2026 · 2nd Quarter (Apr 1 - June 30)
TEVA PHARMACEUTICALS USA INC
Filed by TEVA PHARMACEUTICALS USA, INC..
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 17, 2026
- Income
- Not reported
- Expenses
- $380,000.00
- Registrant
- TEVA PHARMACEUTICALS USA, INC.
- Filing UUID
- 52c0b731-d629-4d3b-8082-025727c84358
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
A joint resolution terminating the national emergency declared to impose duties on articles imported from Canada (S.J.Res.37). Tariff Transparency Act of 2025 (S.959) and Trump Tariff Transparency Act (H.R.6888).
Literal federal measure citations: S.J.Res.37, S.959, H.R.6888
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.